HC010 for first-line PD-L1 positive advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced non-small cell lung cancer (stage IIIB to IV) that is PD-L1 positive.
- You cannot have had any prior chemotherapy or other systemic treatment for advanced lung cancer.
- Your tumor must not have certain gene mutations (like EGFR, ALK, or ROS1).
- You must be able to take care of yourself (ECOG score of 0 or 1) and have a life expectancy of at least 3 months.
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
This trial tests a new drug called HB0025 combined with chemotherapy as the first treatment for advanced squamous non-small cell lung cancer that cannot be removed with surgery. It compares this combination to a standard treatment using another drug called pembrolizumab plus chemotherapy.
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.